2021
Transfusion practices for pediatric oncology and hematopoietic stem cell transplantation patients: Data from the National Heart Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III)
Goel R, Nellis ME, Karam O, Hanson SJ, Tormey CA, Patel RM, Birch R, Sachais BS, Sola‐Visner M, Hauser RG, Luban NLC, Gottschall J, Josephson CD, Hendrickson JE, Karafin MS, Study‐IV‐Pediatric F. Transfusion practices for pediatric oncology and hematopoietic stem cell transplantation patients: Data from the National Heart Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III). Transfusion 2021, 61: 2589-2600. PMID: 34455598, DOI: 10.1111/trf.16626.Peer-Reviewed Original ResearchConceptsInternational normalized ratioBlood Institute Recipient EpidemiologyDonor Evaluation Study-IIINational Heart LungTransfusion practicePediatric oncologyRecipient EpidemiologyHSCT patientsPlasma transfusionRed blood cellsPlatelet countHeart LungHematopoietic stem cell transplantation patientsHematopoietic stem cell transplant patientsMedian international normalized ratioStem cell transplant patientsStem cell transplantation patientsLower INR valuesPre-transfusion HbMedian platelet countMulticenter retrospective studyCell transplant patientsCell transplantation patientsStudy IIIAcute myeloid leukemia
2020
The evanescence and persistence of RBC alloantibodies in blood donors
Hauser RG, Esserman D, Karafin MS, Tan S, Balbuena‐Merle R, Spencer BR, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, Hendrickson JE, Tormey CA, ). The evanescence and persistence of RBC alloantibodies in blood donors. Transfusion 2020, 60: 831-839. PMID: 32061102, DOI: 10.1111/trf.15718.Peer-Reviewed Original ResearchConceptsBlood donorsAntibody persistenceAntibody screenDonor Evaluation Study-IIIHistory of transfusionUS blood centersFit inclusion criteriaPresence of alloantibodiesRecipient EpidemiologyRBC alloantibodiesBlood productsInclusion criteriaSignificant antibodiesBiologic factorsHealthy populationAntibody detectionAntibody identificationAlloantibodiesBlood centersMultiple antibodiesFirst donationAntibody specificityStudy IIIAntibodiesCenter policies
2018
Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III)
Karafin MS, Tan S, Tormey CA, Spencer BR, Hauser RG, Norris PJ, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, Hendrickson JE. Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III). Transfusion 2018, 59: 217-225. PMID: 30427537, DOI: 10.1111/trf.15004.Peer-Reviewed Original ResearchConceptsPositive antibody screenDonor Evaluation Study-IIIAntibody screenRisk factorsRecipient EpidemiologyTransfusion historyBlood centersRBC alloantibodiesBlood donorsRed blood cell alloimmunizationCommon antibody specificitiesPrior transfusion historyRBC alloantibody formationSignificant RBC alloantibodiesHistory of transfusionAdjusted odds ratioMultivariable logistic regressionUS blood centersStudy IIIUS blood donorsPotent immune stimulusFuture medical careHealthy US blood donorsPrior transfusionsPrior pregnancy